Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Hypertens Pregnancy ; 23(1): 121-7, 2004.
Article in English | MEDLINE | ID: mdl-15117606

ABSTRACT

OBJECTIVE: To elicit factors associated with the postpartum development of septic pelvic thrombophlebitis in a single large referral tertiary patient population. METHODS: A nine-year single institution retrospective case review of all patients with enigmatic fever and septic pelvic thrombophlebitis was analyzed. RESULTS: A total of 55 patients with septic pelvic thrombophlebitis were provided care during the study interval. The average gestational age at delivery was 36.8 +/- 4.3 weeks. The most prevalent concurrent medical complication of pregnancy was preeclampsia (45%) while chorioamnionitis affected only 13%. The average length of ruptured membranes was 22.8 +/- 56.8 hours (median 10.5, 95% confidence interval [CI] 7.0-38.7 hours), with 22% of patients undergoing amnion rupture at the time of cesarean delivery. Prolonged (>24 hours) amnion rupture occurred in only 9% of patients. Most affected patients were delivered abdominally (91%) but a minority delivered vaginally (9%). Antibiotic therapy for presumed infection was initiated at 27.4 +/- 24.6 hours postpartum. Subsequently intravenous heparin therapy was initiated 128.9 +/- 54.2 hours thereafter enigmatic fever defervesed 37.2 +/- 36.8 hours later (median 34.0, 95% CI 27.2-47.3 hours). Patients received 6.3 +/- 1.8 days of heparin therapy. CONCLUSION: In this series, septic pelvic thrombophlebitis was frequently preceded by cesarean delivery and commonly associated with preeclampsia. Unexpectedly, a small number of patients suffered prolonged rupture of membranes or chorioamnionitis. We speculate that the cesarean delivery of a population of at-risk patients with preeclampsia may predispose them to develop septic pelvic thrombophlebitis.


Subject(s)
Pelvic Inflammatory Disease/complications , Pelvis/blood supply , Pre-Eclampsia/complications , Sepsis/complications , Thrombophlebitis/complications , Anti-Bacterial Agents/therapeutic use , Body Mass Index , Chorioamnionitis/complications , Chorioamnionitis/drug therapy , Chorioamnionitis/epidemiology , Delivery, Obstetric , Female , Fever/complications , Fever/drug therapy , Fever/epidemiology , Fibrinolytic Agents/therapeutic use , Follow-Up Studies , Gram-Positive Bacterial Infections/complications , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/epidemiology , HELLP Syndrome/complications , HELLP Syndrome/drug therapy , HELLP Syndrome/epidemiology , Heparin/therapeutic use , Humans , Incidence , Maternal Welfare , Mississippi/epidemiology , Pelvic Inflammatory Disease/drug therapy , Pelvic Inflammatory Disease/epidemiology , Pre-Eclampsia/drug therapy , Pre-Eclampsia/epidemiology , Pregnancy , Pregnancy Outcome , Puerperal Infection/complications , Puerperal Infection/drug therapy , Puerperal Infection/epidemiology , Retrospective Studies , Sepsis/drug therapy , Sepsis/epidemiology , Thrombophlebitis/drug therapy , Thrombophlebitis/epidemiology , Trial of Labor , Vancomycin/therapeutic use
2.
Hypertens Pregnancy ; 22(3): 287-94, 2003.
Article in English | MEDLINE | ID: mdl-14572365

ABSTRACT

OBJECTIVE: To determine if the rate of major morbidity from severe preeclampsia with/without hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome differs by parity. METHODS: Retrospective investigation of 970 gravidas with severe preeclampsia with and without HELLP syndrome analyzed according to parity. RESULTS: Altogether 609 (63%) patients were nulliparous and 361 (37%) parous. Between groups there was no significant difference in the incidence of overall major morbidity (21% vs. 19%, p=0.467), or specific morbidities including hematologic/coagulopathic (13.6% vs. 11.9%, p=0.442), cardiopulmonary (8.9% vs. 7.2%, p=0.362), CNS/visual (1.8% vs. 2.8%, p=0.319), or hepatorenal (0.8% vs. 2.2%, p=0.068). Although eclampsia was significantly more common in nulliparous (10.2%) than in parous patients (5.5%, p=0.012), the later significantly more often demonstrated major maternal morbidity associated with eclampsia (50%) than did nulliparous patients (25%, p=0.043). CONCLUSIONS: Unless parous patients with severe preeclampsia with or without HELLP syndrome develop eclampsia, their disease acuity does not differ significantly from their nulliparous counterparts.


Subject(s)
HELLP Syndrome/mortality , Parity/physiology , Adolescent , Adult , Eclampsia/mortality , Female , Humans , Maternal Mortality , Pre-Eclampsia/mortality , Pregnancy , Retrospective Studies
3.
Am J Obstet Gynecol ; 186(6): 1124-9, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12066084

ABSTRACT

OBJECTIVE: The purpose of this study was to compare the efficacy of 3 different techniques of cervical ripening and induction. STUDY DESIGN: Patients who required cervical ripening and induction were randomized to one of 3 groups: (1) supracervical Foley catheter and intravaginal dinoprostone gel, (2) supracervical Foley catheter and 100 microg oral doses of misoprostol, or (3) serial 100-microg oral doses of misoprostol. Intravenous oxytocin was administered when a protraction disorder of labor was identified. RESULTS: There were 339 women randomized. There was no significant difference in the time from first intervention to delivery in the 3 groups (P =.546). In each group, a similar percentage of women required oxytocin (P =.103). The rates of cesarean delivery were equivalent among the groups (P =.722). Rates of tachysystole were high but statistically equivalent among the 3 groups. There were no significant differences in Apgar scores or umbilical artery pH. CONCLUSION: Oral 100 microg serial doses of misoprostol, with or without the use of a supracervical Foley catheter, were equivalent to the use of a supracervical Foley catheter and serial 4-mg doses of dinoprostone gel for cervical ripening and the induction of labor.


Subject(s)
Catheterization , Cervical Ripening , Dinoprostone/therapeutic use , Labor, Induced/methods , Misoprostol/therapeutic use , Oxytocics/therapeutic use , Adult , Cesarean Section/statistics & numerical data , Delivery, Obstetric , Dinoprostone/adverse effects , Female , Gels , Humans , Misoprostol/adverse effects , Oxytocics/adverse effects , Oxytocin/therapeutic use , Pregnancy , Survival Analysis , Tachycardia, Paroxysmal/chemically induced , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...